The US House of Representatives recently passed the Biosecure Act, which includes the US’s biological sanctions against China. The bill will now head to the US Senate for voting and go through a presidential review process for legislation.

The Biosecure Act restricts transactions with major Chinese biotech companies that the U.S. Congress deems to pose a threat to national security. The US Congress has categorized the biotechs into 3 groups, A, B, and C. Group A includes 5 companies: BGI, MGI, and Complete Genomics, which are genomic equipment manufacturers and analytical services, and Wuxi AppTec and Wuxi Biologics, which are contract development and manufacturing organizations (CDMOs).